phrykt

Elite Pharmaceuticals Inc /Nv/ (ELTP): who owns it and who trades it

As of Nov 3, 2026, ELTP insiders reported 2 purchases worth $34.7K in the last 12 months. The largest buyer was Barry H Dash (Director), with $34.7K.

Latest filing Nov 3, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, ELTP insiders reported $34.7K of open-market purchases and $0 of sales.

Purchases, 12 months
$34.7K
2 trades, 1 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Oct 9, 2026
Filed Oct 19, 2026

Purchases and sales by month

$26K$26KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 9, 2026Barry H DashDirectorPurchase100,000$0.26$26KForm 4
Aug 19, 2026Barry H DashDirectorPurchase30,000$0.29$8.7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Barry H DashDirector$34.7K–Oct 9, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ELTP short interest

Low short interest. 0.3% of ELTP shares are sold short: about 1 share in 360. Over the last 12 reports the number of shares short went up 14%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 2.99M ELTP shares were sold short, 0.3% of the shares outstanding, down 1.4% from the report before. At the average daily volume of 1.08M shares, buying them all back would take about 2.8 trading days (days to cover).

Shares short, % of all shares

0.28%May 15Oct 300.29%

Days to cover

2.8May 15Oct 304.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20262.99M0.28%-1%1.08M2.8
Oct 15, 20263.03M0.28%+15%1.74M1.8
Sep 30, 20262.63M0.24%+1%1.18M2.2
Sep 15, 20262.61M0.24%+2%1.69M1.6
Aug 31, 20262.55M0.24%+1%1.88M1.4
Aug 14, 20262.51M0.23%-7%2.01M1.2
Jul 31, 20262.69M0.25%+3%720,4213.7
Jul 15, 20262.60M0.24%-2%1.37M1.9
Jun 30, 20262.65M0.25%+2%1.29M2.0
Jun 15, 20262.59M0.24%-0%1.70M1.5
May 29, 20262.60M0.24%-1%801,1383.2
May 15, 20262.62M0.24%+6%1.00M2.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Elite Pharmaceuticals company events

Elite Pharmaceuticals filed 12 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 3, 2026.

  1. Nov 3, 2026LeadershipThe Board of Directors of Elite Pharmaceuticals, Inc. increased the size of the Board from four to six directors and unanimously elected Aqeel A. Fatmi, Ph.D., and John W. LaRocca, Esq., as Class II and Class I directors of the Company, respectively, effective October 28, 2026. Filing
  2. Aug 13, 2026ResultsReleased financial results. Filing
  3. Aug 11, 2026AnnouncementAmended an earlier report. Shared information with investors. Filing
  4. Aug 10, 2026AnnouncementShared information with investors. Filing
  5. Aug 4, 2026AnnouncementShared information with investors. Filing
  6. Jun 29, 2026ResultsReleased financial results. Filing
  7. Jun 23, 2026AnnouncementShared information with investors. Filing
  8. Jun 15, 2026AnnouncementShared information with investors. Filing
  9. Jun 1, 2026AnnouncementShared information with investors. Filing
  10. Apr 2, 2026AnnouncementShared information with investors. Filing
  11. Feb 17, 2026ResultsReleased financial results. Filing
  12. Feb 11, 2026AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Elite Pharmaceuticals financials

Questions about Elite Pharmaceuticals Inc /Nv/ (ELTP) stock

Are ELTP insiders buying or selling?

In the last 12 months, ELTP insiders reported 2 open-market purchases worth $34.7K and no sales. The latest trade was on Oct 9, 2026. See every trade.

What is the short interest in ELTP?

As of Oct 30, 2026, 2.99M ELTP shares were sold short, 0.3% of the shares outstanding, down 1.4% from the report before. At the average daily volume of 1.08M shares, buying them all back would take about 2.8 trading days (days to cover). See the history.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.